Literature DB >> 14630633

Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity.

Jo El J Schultz1, Betty J Glascock, Sandra A Witt, Michelle L Nieman, Kalpana J Nattamai, Lynne H Liu, John N Lorenz, Gary E Shull, Thomas R Kimball, Muthu Periasamy.   

Abstract

We recently developed a mouse model with a single functional allele of Serca2 (Serca2+/-) that shows impaired cardiac contractility and relaxation without overt heart disease. The goal of this study was to test the hypothesis that chronic reduction in sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA)2 levels in combination with an increased hemodynamic load will result in an accelerated pathway to heart failure. Age-matched wild-type and Serca2+/- mice were subjected to 10 wk of pressure overload via transverse aortic coarctation surgery. Cardiac hypertrophy and heart failure were assessed by echocardiography, gravimetry/histology, hemodynamics, and Western blotting analyses. Our results showed that approximately 64% of coarcted Serca2+/- mice were in heart failure compared with 0% of coarcted wild-type mice (P < 0.05). Overall, morbidity and mortality were greatly increased in Serca2+/- mice under pressure overload. Echocardiography assessment revealed a significant increase in left ventricular (LV) mass, and LV hypertrophy in coarcted Serca2+/- mice converted from a concentric to an eccentric pattern, similar to that seen in human heart failure. Coarcted Serca2+/- mice had decreased contractile/systolic and relaxation/diastolic performance and/or function compared with coarcted wild-type mice (P < 0.05), despite a similar duration and degree of pressure overload. SERCA2a protein levels were significantly reduced (>50%) in coarcted Serca2+/- mice compared with noncoarcted and coarcted wild-type mice. Our findings suggest that reduction in SERCA2 levels in combination with an increased hemodynamic load results in an accelerated pathway to heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14630633     DOI: 10.1152/ajpheart.00720.2003

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  37 in total

Review 1.  Cardiac gene therapy with SERCA2a: from bench to bedside.

Authors:  Judith K Gwathmey; Alexan I Yerevanian; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2010-11-18       Impact factor: 5.000

Review 2.  The Ca2+ ATPase of cardiac sarcoplasmic reticulum: Physiological role and relevance to diseases.

Authors:  Giuseppe Inesi; Anand Mohan Prasad; Rajendra Pilankatta
Journal:  Biochem Biophys Res Commun       Date:  2007-12-07       Impact factor: 3.575

3.  Persistent overexpression of SERCA2a affects bladder functions under physiological conditions, but not in bladder outlet obstruction-induced sub-acute pathological conditions.

Authors:  Atsushi Yamada; Kazumasa Torimoto; Koji Obata; Akihide Hirayama; Kiyohide Fujimoto; Miyako Takaki
Journal:  J Physiol Sci       Date:  2013-09-14       Impact factor: 2.781

Review 4.  Gene therapy in heart failure.

Authors:  Leif Erik Vinge; Philip W Raake; Walter J Koch
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

5.  Enhanced SERCA2A expression improves contractile performance of ventricular cardiomyocytes of rat under adrenergic stimulation.

Authors:  A Anwar; K-D Schlüter; J Heger; H M Piper; G Euler
Journal:  Pflugers Arch       Date:  2008-06-26       Impact factor: 3.657

Review 6.  Gene therapy targets in heart failure: the path to translation.

Authors:  P W J Raake; H Tscheschner; J Reinkober; J Ritterhoff; H A Katus; W J Koch; P Most
Journal:  Clin Pharmacol Ther       Date:  2011-08-24       Impact factor: 6.875

7.  Calcium handling precedes cardiac differentiation to initiate the first heartbeat.

Authors:  Richard Cv Tyser; Antonio Ma Miranda; Chiann-Mun Chen; Sean M Davidson; Shankar Srinivas; Paul R Riley
Journal:  Elife       Date:  2016-10-11       Impact factor: 8.140

8.  Force development and intracellular Ca2+ in intact cardiac muscles from gravin mutant mice.

Authors:  Zhitao Li; Sonal Singh; Santosh V Suryavanshi; Wengang Ding; Xiaoxu Shen; Cori S Wijaya; Wei Dong Gao; Bradley K McConnell
Journal:  Eur J Pharmacol       Date:  2017-04-17       Impact factor: 4.432

Review 9.  Understanding How Phosphorylation and Redox Modifications Regulate Cardiac Ryanodine Receptor Type 2 Activity to Produce an Arrhythmogenic Phenotype in Advanced Heart Failure.

Authors:  Alexander Dashwood; Elizabeth Cheesman; Nicole Beard; Haris Haqqani; Yee Weng Wong; Peter Molenaar
Journal:  ACS Pharmacol Transl Sci       Date:  2020-06-01

Review 10.  Heart failure management: the present and the future.

Authors:  Mohammad N Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.